Target intelligence / Profile preview

Suppression of enteric pathogens via bacteriocins

Molecular classification
Other (mechanism/process)
01

Overview

Suppression of enteric pathogens via bacteriocins is a protective mechanism in the gut where commensal microbes produce small, ribosomally synthesized peptides called bacteriocins to inhibit or kill pathogenic bacteria. This natural antagonism helps maintain gut health, prevents infections, and shapes the microbial ecosystem. The process is mediated by various species (notably Lactobacillus, Streptococcus, Clostridium, and Bacillus) that produce different classes and families of bacteriocins, which act through mechanisms such as pore formation, membrane disruption, resource competition, and modulation of the host immune response. This process underlies the concept of "colonization resistance" and is a major reason why probiotics and certain bacteriocins are studied as preventive or adjunctive therapies for gastrointestinal infections and dysbiosis.

Other names
Bacteriocin-mediated suppression of enteric pathogensGut microbial antagonism via bacteriocinsBacteriocin-driven colonization resistance
02

Mechanism of action

The mechanism involves direct killing or inhibition of pathogens via pore formation or membrane disruption by bacteriocins, niche exclusion by occupying space and resources to prevent pathogen colonization, and immune modulation through enhancement of host defenses against pathogens.

03

Biological functions

Antimicrobial activityCompetitive exclusion of pathogensColonization resistanceModulation of gut microbiotaImmune modulation
04

Disease associations

Infection (preventing or reducing enteric pathogens such as Listeria, Salmonella, Shigella, Clostridioides difficile, etc.)Inflammatory and immune-mediated diseases (related to dysbiosis)General maintenance of intestinal health
05

Safety considerations

Limited toxicity in hosts due to peptide degradationPotential for dysbiosis if commensal populations are disrupted (e.g. by antibiotics), reducing bacteriocin productionResistance is reportedly less common than with antibiotics, but concerns remain for misuse of purified bacteriocins
06

Interacting drugs

Bacteriocins as biologics (such as nisin, plantaricin, and Abp118)

1 more in the full profile.

07

Biomarkers

Gut microbiota composition (increase in bacteriocin-producing commensals)Presence/levels of specific bacteriocins (as measured by molecular assays)

Beyond the preview

Go deeper on Suppression of enteric pathogens via bacteriocins.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Suppression of enteric pathogens via bacteriocins.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call